UBS(Lux)E.F.-Biotech(USD)P a.SEK/ LU1991432631 /
| NAV2024-07-24 | Chg.-4.5100 | Type of yield | Investment Focus | Investment company |
|---|---|---|---|---|
| 1,053.6600SEK | -0.43% | reinvestment | Equity Worldwide | UBS Fund M. (LU) ▶ |
Monthly performance
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | - | -2.50 | 0.65 | -0.87 | -3.03 | 12.11 | -0.97 | 5.56 | -5.13 | -4.80 | 1.18 | 2.38 | +0.74% |
| 2022 | -8.92 | -1.62 | 2.79 | -5.31 | -4.00 | 10.88 | 0.91 | 9.71 | 3.35 | 4.98 | 3.19 | -8.29 | +5.52% |
| 2023 | 1.81 | -6.40 | 0.23 | -0.46 | 3.19 | 0.27 | -0.13 | 2.14 | -4.89 | -6.31 | -1.50 | 11.39 | -1.89% |
| 2024 | -0.42 | -0.51 | 5.17 | -6.01 | 4.62 | 4.50 | 6.60 | - | - | - | - | - | - |
Calculated values
| YTD | 6 Months | 1 Year | 3 Years | 5 Years | |
|---|---|---|---|---|---|
| Volatility | 18.93% | 18.97% | 19.30% | 22.73% | -% |
| Sharpe ratio | 1.21 | 1.17 | 0.60 | 0.08 | - |
| Best month | +11.39% | +6.60% | +11.39% | +11.39% | - |
| Worst month | -6.01% | -6.01% | -6.31% | -8.92% | - |
| Maximum loss | -9.77% | -8.26% | -15.54% | -24.75% | - |
| Outperformance | - | - | - | - | - |
All quotes in SEK
Share classes
| Name | Type of yield | Repurchase p. | 1 Year | 3 Years | |
|---|---|---|---|---|---|
| UBS(Lux)E.F.-Biotech(USD)P a.SEK | reinvestment | 1,053.6600 | +15.18% | +17.15% | |
| UBS(Lux)E.F.-Biotech(USD)QL a.US... | reinvestment | 110.6300 | +12.65% | -2.61% | |
| UBS(Lux)E.F.-Biotech(USD)Q a.USD | reinvestment | 340.1500 | +12.42% | -3.19% | |
| UBS (Lux) Equity Fund - Biotech ... | reinvestment | 108.1100 | +14.75% | - | |
| UBS (Lux) Equity Fund - Biotech ... | reinvestment | 766.3100 | +11.28% | -6.11% |
Performance
| YTD | +14.14% | ||
|---|---|---|---|
| 6 Months | +12.14% | ||
| 1 Year | +15.18% | ||
| 3 Years | +17.15% | ||
| 5 Years | - | ||
| 10 Years | - | ||
| Since start | +19.04% | ||
| Year | |||
| 2023 | -1.89% | ||
| 2022 | +5.52% | ||
| 2021 | +0.74% | ||
